ClinicalTrials.gg
CompletedNCT01262118Updated Jan 23, 2013Results posted

Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis

A Phase 1 interventional study of CP-690,550 (tasocitinib) in Rheumatoid Arthritis, sponsored by Pfizer. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-23.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
69
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing tofacitinib in Arthritis, Rheumatoid — 9 open to participants now, 9 under way, 1 of them phase 3. tofacitinib · Arthritis, Rheumatoid.

Enrollment
34th of 43
69 · median 170
Started
2011
with 1 other
Phase 1
6 of 43
none open now
Registered
18th of 43
by date
Lead sponsor
25 of 43
Pfizer

Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, this one is the 34th largest by enrollment, is one of 2 that started in 2011, is one of 6 in phase 1, and was the 18th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

9 of the 43 studies testing tofacitinib in Arthritis, Rheumatoid are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tofacitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of study is to explore the effect of CP-690,550 (tasocitinib) on cholesterol metabolism in patients with active rheumatoid arthritis (RA).

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Cholesterol metabolism
  • Cholesterol flux
  • Rheumatoid Arthritis
  • Tasocitinib
  • CP-690
  • 550
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females, 18 years of age or older with active rheumatoid arthritis; Or male and female healthy volunteers 18 years of age and older

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women
  • systemic disease (other than RA for RA arm)
  • Use of lipid-regulating agents
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    CP-690,550 (tasocitinib) 10 mg twice daily (BID)

    Drug: CP-690,550 (tasocitinib)

  • No intervention
    Healthy Volunteers

    No intervention

Interventions

  • CP-690,550 (tasocitinib) dosed at 10 mg BID for 6 weeks in patients with active rheumatoid arthritis

06

What researchers measure

Primary outcomes

  1. High-density Lipoprotein Cholesterol (HDL-C) Concentration at Baseline

    Blood level of HDL-C was measured following a 12-hours fasting.

    Time frame: Baseline

  2. High-density Lipoprotein Cholesterol (HDL-C) Concentration at Week 6

    Blood level of HDL-C was measured following a 12-hours fasting.

    Time frame: Week 6

  3. Cholesterol Ester Production Rate at Baseline

    Cholesterol ester production rate was calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program.

    Time frame: Baseline

  4. Cholesterol Ester Production Rate at Week 6

    Cholesterol ester production rate was calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program.

    Time frame: Week 6

Secondary outcomes

  1. Low-density Lipoprotein Cholesterol (LDL-C) and Total Cholesterol Concentration

    Blood level of LDL-C and total cholesterol (TC) was measured following a 12-hours fasting.

    Time frame: Baseline, Week 6

  2. Cholesterol Ester Fractional Catabolic Rate

    Cholesterol ester fractional catabolic rate were calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program. Fractional catabolic rate was the percentage of cholesterol ester which was replaced, transferred or lost per unit of time.

    Time frame: Baseline, Week 6

  3. Low-density Lipoprotein Associated With Apolipoprotein B (LDL-apoB) Production Rate

    LDL-apoB production rate were calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program.

    Time frame: Baseline, Week 6

  4. Low-density Lipoprotein Associated With Apolipoprotein B (LDL-apoB) Fractional Catabolic Rate

    Fractional catabolic rate for LDL ApoB were calculated using the 13 carbon (13C) isotopic enrichment of very low density lipoprotein (VLDL) as the limiting value. Isotope 13C in plasma was measured using Gas Chromatography-Combustion-Isotope Ratio Mass Spectrometry (GC-C-IRMS).

    Time frame: Baseline, Week 6

  5. High-density Lipoprotein Associated With Apolipoprotein A1 (HDL-apoA1) Production Rate

    HDL-apoA1 production rate were calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program.

    Time frame: Baseline, Week 6

  6. High-density Lipoprotein Associated With Apolipoprotein A1 (HDL-apoA1) Fractional Catabolic Rate

    Fractional catabolic rate for HDL-apoA1 were calculated using the 13C isotopic enrichment of VLDL as the limiting value. Isotope 13C in plasma was measured using GC-C-IRMS.

    Time frame: Baseline, Week 6

  7. Cholesterol Efflux Rate

    Cholesterol efflux rate was measured using isotope dilution method in which rate of appearance of isotope 13C-free cholesterol in plasma representing whole body efflux from tissues was assessed. Isotope 13C in plasma was measured using GC-C-IRMS.

    Time frame: Baseline, Week 6

07

Results

Posted Jan 23, 2013

Participant flow

Baseline Assessment Period (3 Days)
Participant flow — Baseline Assessment Period (3 Days)
MilestoneRheumatoid Arthritis CohortHealthy Volunteers Cohort
Started3633
Completed3633
Not completed00
Treatment Period (6 Weeks)
Participant flow — Treatment Period (6 Weeks)
MilestoneRheumatoid Arthritis CohortHealthy Volunteers Cohort
Started360
Completed360
Not completed00

Outcome measures

PrimaryHigh-density Lipoprotein Cholesterol (HDL-C) Concentration at Baseline

Blood level of HDL-C was measured following a 12-hours fasting.

Time frame:
Baseline
Reported as:
Mean · milligram per deciliter (mg/dL)
High-density Lipoprotein Cholesterol (HDL-C) Concentration at Baseline
milligram per deciliter (mg/dL)Rheumatoid Arthritis CohortHealthy Volunteer Cohort
High-density Lipoprotein Cholesterol (HDL-C) Concentration at Baseline54.30 ± 12.5263.43 ± 16.89
PrimaryHigh-density Lipoprotein Cholesterol (HDL-C) Concentration at Week 6

Blood level of HDL-C was measured following a 12-hours fasting.

Time frame:
Week 6
Reported as:
Mean · mg/dL
High-density Lipoprotein Cholesterol (HDL-C) Concentration at Week 6
mg/dLRheumatoid Arthritis Cohort
High-density Lipoprotein Cholesterol (HDL-C) Concentration at Week 662.34 ± 15.24
PrimaryCholesterol Ester Production Rate at Baseline

Cholesterol ester production rate was calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program.

Time frame:
Baseline
Reported as:
Mean · (mg per kilogram) per hour ([mg/kg]/hr)
Cholesterol Ester Production Rate at Baseline
(mg per kilogram) per hour ([mg/kg]/hr)Rheumatoid Arthritis CohortHealthy Volunteer Cohort
Cholesterol Ester Production Rate at Baseline1.09 ± 0.241.11 ± 0.26
PrimaryCholesterol Ester Production Rate at Week 6

Cholesterol ester production rate was calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program.

Time frame:
Week 6
Reported as:
Mean · (mg/kg)/hr
Cholesterol Ester Production Rate at Week 6
(mg/kg)/hrRheumatoid Arthritis Cohort
Cholesterol Ester Production Rate at Week 61.12 ± 0.24
SecondaryLow-density Lipoprotein Cholesterol (LDL-C) and Total Cholesterol Concentration

Blood level of LDL-C and total cholesterol (TC) was measured following a 12-hours fasting.

Time frame:
Baseline, Week 6
Reported as:
Mean · mg/dL
Low-density Lipoprotein Cholesterol (LDL-C) and Total Cholesterol Concentration
mg/dLRheumatoid Arthritis CohortHealthy Volunteer Cohort
Baseline: LDL-C124.61 ± 28.55144.88 ± 36.36
Baseline: TC193.79 ± 32.56221.57 ± 42.12
Week 6: LDL-C142.68 ± 39.02NA ± NA
Week 6: TC219.83 ± 41.33NA ± NA
SecondaryCholesterol Ester Fractional Catabolic Rate

Cholesterol ester fractional catabolic rate were calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program. Fractional catabolic rate was the percentage of cholesterol ester which was replaced, transferred or lost per unit of time.

Time frame:
Baseline, Week 6
Reported as:
Mean · percentage ester per hour (%/hr)
Cholesterol Ester Fractional Catabolic Rate
percentage ester per hour (%/hr)Rheumatoid Arthritis CohortHealthy Volunteer Cohort
Baseline2.43 ± 0.392.17 ± 0.36
Week 62.23 ± 0.31NA ± NA
SecondaryLow-density Lipoprotein Associated With Apolipoprotein B (LDL-apoB) Production Rate

LDL-apoB production rate were calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program.

Time frame:
Baseline, Week 6
Reported as:
Mean · (mg/kg)/hr
Low-density Lipoprotein Associated With Apolipoprotein B (LDL-apoB) Production Rate
(mg/kg)/hrRheumatoid Arthritis CohortHealthy Volunteer Cohort
Baseline0.49 ± 0.120.50 ± 0.13
Week 60.52 ± 0.12NA ± NA
SecondaryLow-density Lipoprotein Associated With Apolipoprotein B (LDL-apoB) Fractional Catabolic Rate

Fractional catabolic rate for LDL ApoB were calculated using the 13 carbon (13C) isotopic enrichment of very low density lipoprotein (VLDL) as the limiting value. Isotope 13C in plasma was measured using Gas Chromatography-Combustion-Isotope Ratio Mass Spectrometry (GC-C-IRMS).

Time frame:
Baseline, Week 6
Reported as:
Mean · %/hr
Low-density Lipoprotein Associated With Apolipoprotein B (LDL-apoB) Fractional Catabolic Rate
%/hrRheumatoid Arthritis CohortHealthy Volunteer Cohort
Baseline1.61 ± 0.371.50 ± 0.35
Week 61.57 ± 0.41NA ± NA
SecondaryHigh-density Lipoprotein Associated With Apolipoprotein A1 (HDL-apoA1) Production Rate

HDL-apoA1 production rate were calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program.

Time frame:
Baseline, Week 6
Reported as:
Mean · mg/kg/hr
High-density Lipoprotein Associated With Apolipoprotein A1 (HDL-apoA1) Production Rate
mg/kg/hrRheumatoid Arthritis CohortHealthy Volunteer Cohort
Baseline0.57 ± 0.110.59 ± 0.16
Week 60.65 ± 0.15NA ± NA
SecondaryHigh-density Lipoprotein Associated With Apolipoprotein A1 (HDL-apoA1) Fractional Catabolic Rate

Fractional catabolic rate for HDL-apoA1 were calculated using the 13C isotopic enrichment of VLDL as the limiting value. Isotope 13C in plasma was measured using GC-C-IRMS.

Time frame:
Baseline, Week 6
Reported as:
Mean · %/hr
High-density Lipoprotein Associated With Apolipoprotein A1 (HDL-apoA1) Fractional Catabolic Rate
%/hrRheumatoid Arthritis CohortHealthy Volunteer Cohort
Baseline1.08 ± 0.221.02 ± 0.22
Week 61.11 ± 0.28NA ± NA
SecondaryCholesterol Efflux Rate

Cholesterol efflux rate was measured using isotope dilution method in which rate of appearance of isotope 13C-free cholesterol in plasma representing whole body efflux from tissues was assessed. Isotope 13C in plasma was measured using GC-C-IRMS.

Time frame:
Baseline, Week 6
Reported as:
Mean · (mg/kg)/hr
Cholesterol Efflux Rate
(mg/kg)/hrRheumatoid Arthritis CohortHealthy Volunteer Cohort
Baseline4.02 ± 0.964.35 ± 1.53
Week 64.04 ± 1.08NA ± NA

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rheumatoid Arthritis Cohort—0/36 (0%)19/36 (52.8%)
Healthy Volunteer Cohort—0/33 (0%)6/33 (18.2%)
Most frequent other events
Showing 10 of 31
Most frequent other events
EventRheumatoid Arthritis CohortHealthy Volunteer Cohort
Upper respiratory tract infectionInfections and infestations7/360/33
HeadacheNervous system disorders4/364/33
Urinary tract infectionInfections and infestations3/360/33
Abdominal distensionGastrointestinal disorders2/360/33
DyspepsiaGastrointestinal disorders2/360/33
Oedema peripheralGeneral disorders1/361/33
MigraineNervous system disorders1/361/33
Abdominal pain upperGastrointestinal disorders1/360/33
DiarrhoeaGastrointestinal disorders1/360/33
Gastrooesophageal reflux diseaseGastrointestinal disorders1/360/33

Baseline characteristics

Age, Customized
Age, Customized(participants)Rheumatoid Arthritis CohortHealthy Volunteers CohortTotal
18 to 44 years9716
45 to 64 years252550
Greater than or equal to (>=) 65 years213
Sex: Female, Male
Sex: Female, Male(Participants)Rheumatoid Arthritis CohortHealthy Volunteers CohortTotal
Female302858
Male6511
08

Study locations

11 sites
  • Pfizer Investigational Site
    Anniston, Alabama 36201, United States
  • Pfizer Investigational Site
    Anniston, Alabama 36207, United States
  • Pfizer Investigational Site
    Little Rock, Arkansas 72201, United States
  • Pfizer Investigational Site
    Los Angeles, California 90095, United States
  • Pfizer Investigational Site
    Daytona Beach, Florida 32114, United States
  • Pfizer Investigational Site
    Ormond Beach, Florida 32174, United States
  • Pfizer Investigational Site
    South Miami, Florida 33143, United States
  • Pfizer Investigational Site
    Bingham Farms, Michigan 48025, United States
  • Pfizer Investigational Site
    Dallas, Texas 75231, United States
  • Pfizer Investigational Site
    Balatonfured, 8230, Hungary
  • Pfizer Investigational Site
    Budapest, 1032, Hungary
09

References and documents

Publications

  • Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6. PubMed 34870800 ↗
  • Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395. PubMed 33127856 ↗
  • Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2021 Sep;66(9):3214-3215. doi: 10.1007/s10620-020-06638-z. PubMed 32816215 ↗
  • Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017 Jul;76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31. PubMed 28143815 ↗
  • Charles-Schoeman C, Fleischmann R, Davignon J, Schwartz H, Turner SM, Beysen C, Milad M, Hellerstein MK, Luo Z, Kaplan IV, Riese R, Zuckerman A, McInnes IB. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol. 2015 Mar;67(3):616-25. doi: 10.1002/art.38974. PubMed 25470338 ↗
  • Cohen S, Radominski SC, Gomez-Reino JJ, Wang L, Krishnaswami S, Wood SP, Soma K, Nduaka CI, Kwok K, Valdez H, Benda B, Riese R. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014 Nov;66(11):2924-37. doi: 10.1002/art.38779. PubMed 25047021 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Jan 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2010
First posted
Dec 17, 2010
Start
May 2011
Primary completionActual
Jan 2012
CompletionActual
Feb 2012
Results first posted
Jan 23, 2013
Last update
Jan 23, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01262118
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 17, 2010
Start date
May 2011
Primary completion
Jan 2012
Completion
Feb 2012
Results posted
Jan 23, 2013
Last update
Jan 23, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion